• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vertex Pharmaceuticals (NQ:VRTX)

    528.04 +30.03 (+6.03%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Vertex Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    66 67 Next >
    News headline image
    While SpaceX Gets the Headlines, Smart Investors Are Loading Up on This Stock Instead ↗
    This big biotech stock doesn't get the hype that SpaceX does. But it could be the smarter bet right now. 
    Via The Motley Fool
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? ↗
    Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value. 
    Via The Motley Fool
    News headline image
    Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? ↗
    Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk profiles and financials compare? 
    Via The Motley Fool
    Vertex Pharmaceuticals (NASDAQ:VRTX): A GARP Growth Stock with Reasonable Valuation and Strong Fundamentals ↗
    Via Chartmill
    VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX): Affordable Growth with Strong Fundamentals ↗
    Via Chartmill
    Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Meets a Technical Setup for a Potential Breakout ↗
    Via Chartmill
    Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Fits the Affordable Growth Profile With Strong Earnings and Reasonable Valuation ↗
    Via Chartmill
    News headline image
    Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)
    Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers. ... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    $100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗
    Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 8.53% on an annualized basis producing an average annual return of 19.73%. Currently, Vertex Pharmaceuticals... 
    Via Benzinga
    News headline image
    CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
    From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles. 
    Via The Motley Fool
    News headline image
    The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗
    The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout. 
    Via MarketBeat
    Topics ETFs
    News headline image
    The Best Stocks to Invest $1,000 in Right Now ↗
    Exploring some of the top bargains in a multi-trillion-dollar industry. 
    Via The Motley Fool
    News headline image
    3 of Wall Street’s Favorite Stocks to Consider Right Now
    The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
    Via StockStory
    News headline image
    2 Reasons to Like VRTX (and 1 Not So Much)
    Vertex Pharmaceuticals has been treading water for the past six months, recording a small loss of 1.6% while holding steady at $452.99. The stock also fell s... 
    Via StockStory
    News headline image
    If I Had to Start Over With $1,000 in Stocks Today, Here's Exactly What I'd Buy ↗
    These well-established companies are on track to deliver more growth. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks. ↗
    These companies don't typically compete directly with one another, but that might change soon. 
    Via The Motley Fool
    News headline image
    Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year ↗
    The opportunity is enormous, but uncertainty remains. 
    Via The Motley Fool
    News headline image
    3 Market-Beating Stocks Worth Investigating
    Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ... 
    Via StockStory
    News headline image
    The Best Biotech Stocks to Buy in 2026 ↗
    They have at least one thing in common: An exciting pipeline. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? ↗
    A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook. 
    Via The Motley Fool
    News headline image
    CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? ↗
    The company seems to be doing everything it's supposed to be doing; the stock just isn't responding. 
    Via The Motley Fool
    News headline image
    The Best Stocks to Invest $500 in Right Now ↗
    The market is underestimating these companies' long-term prospects. 
    Via The Motley Fool
    News headline image
    2 Healthcare Stocks with Exciting Potential and 1 Facing Challenges
    Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloade... 
    Via StockStory
    News headline image
    Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗
    Are there significant gains ahead for one (or both) of these innovative biotechs? 
    Via The Motley Fool
    Which S&P500 stocks are moving on Tuesday? ↗
    Via Chartmill
    News headline image
    1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? ↗
    The biotech's innovative platform could pay off. 
    Via The Motley Fool
    News headline image
    5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call
    Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management hi... 
    Via StockStory
    Topics Earnings
    News headline image
    Is This Millionaire-Maker Biotech Stock a Buy Right Now? ↗
    The market wasn't impressed by its latest quarterly update. 
    Via The Motley Fool
    Topics Initial Public Offering
    News headline image
    Vertex (VRTX) Q1 2026 Earnings Call Transcript ↗
    Vertex (VRTX) Q1 2026 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Vertex Pharmaceuticals Reports Mixed Q1 Results ↗
    Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports financial results for the first quarter after the market close on Monday. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    66 67 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.